HDAC inhibitors can attenuate DNA damage repair and suppress the expression of BRCA1 in many tumors including cervical, head and neck cancer, prostate, ovarian, and breast cancers 63, 64, 65, 66, 67, 68. This evidence concerns the gene HDAC9 and breast cancer.